New marburg vaccine shows promise in early human trial
NCT ID NCT06265012
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a new vaccine called PHV01 against Marburg virus, a rare but severe disease. 36 healthy adults received either the vaccine or a placebo to check safety and immune response. The study aims to find a safe dose and see if the vaccine triggers antibodies against the virus.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Marburg virus vaccine (PHV01)
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent Marburg virus disease, a rare but often fatal illness.
- What could go wrong
- This is an early Phase 1 trial with only 36 people, so results may not apply to larger populations. The vaccine may not produce a strong enough immune response or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
36 people
The number who actually took part.
- Started
-
Feb 2024
- Finished
-
Sep 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy, adult, male or non-pregnant, non-lactating females, age 18-60 years * Given written informed consent * No clinically significant health problems * Negative test for SARS-CoV-2 * Agree to avoid conception through Day 29 * Agree to minimize blood and body fluid exposures to others after vaccination through Day 29 * Agree to avoid exposure to immunocompromised persons after vaccination through Day 29 Exclusion Criteria: * Prior infection with Marburg virus, related filovirus, or Ebola virus * Prior infection with vesicular stomatitis virus (VSV) * Received any VSV-vectored vaccine * BMI of ≥ 35 * Household contact who is immunodeficient, or on immunosuppressive medication * Hepatitis B, hepatitis C, HIV-1, HIV-2, history of long COVID, diabetes, atopic dermatitis (eczema), chronic inflammatory disease, autoimmune or autoinflammatory disorder, malignancy, chronic or active neurologic disorder * History of severe reactions to any vaccine or history of severe allergies * Receipt of investigational product up to 30 days prior to randomization * Receipt of licensed or authorized non-live vaccines within 14 days of planned study immunization (30 days for live vaccines). * Known allergy to components of PHV01 * Injection sites obscured by tattoos or physical condition * Significant psychiatric or medical condition or laboratory abnormality on screening * History of Guillain Barre Syndrome or any chronic or acute neurological disorder * Alcohol or illicit drug abuse within past 5 years * Pregnant or lactating female * Administration of blood or IgG within 60 days preceding study * Administration of systemic chronic immunosuppressants (defined as more than 14 days) or other immune modifying drugs within 6 months of study entry * History of blood donation within 60 days of study * Unwilling to undergo diagnostic evaluation of rash (skin biopsy, if indicated) or joint symptoms (arthrocentesis if indicated by joint effusion), in both cases if acceptable to subject * Elective surgery planned during the study period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Marburg virus disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExel RCA
Hollywood, Florida, 33024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.